Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock

      Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock

PR Newswire

WASHINGTON, Aug. 7, 2013

WASHINGTON, Aug. 7, 2013 /PRNewswire/ --Vanda Pharmaceuticals Inc. (Vanda)
(NASDAQ: VNDA) today announced the sale of 4,680,000 shares of its common
stock in an underwritten public offering at a price to the public of $11.14
per share. The net offering proceeds to Vanda from the sale of the shares are
expected to be approximately $48.3 million, after deducting underwriting
discounts and commissions and other estimated offering expenses, but excluding
any exercise of the underwriters' over-allotment option.

Vanda anticipates using the net proceeds from this offering for sales and
marketing expenditures which may include commercial launch activities for
tasimelteon for the treatment of Non-24-Hour Disorder following the receipt of
regulatory approval, if any, research and development activities and other
general corporate purposes. The offering is expected to close on or about
August 12, 2013, subject to customary closing conditions. In addition, Vanda
has granted the underwriters a 30-day option to purchase up to an additional
702,000 shares of common stock on the same terms and conditions, solely to
cover over-allotments, if any.

Lazard Capital Markets LLC and Piper Jaffray & Co. are acting as the joint
book-running managers and JMP Securities LLC is acting as co-manager for the
offering.

The shares described above will be issued pursuant to a prospectus supplement
filed as part of a shelf registration statement on Form S-3 previously filed
with and declared effective by the Securities and Exchange Commission (SEC).
The offering may be made only by means of a prospectus supplement and the
accompanying prospectus, copies of which may be obtained by sending a request
to: Lazard Capital Markets LLC, 30 Rockefeller Plaza, New York, NY 10020 or
via telephone at (800) 542-0970 or the offices of Piper Jaffray & Co., by mail
at 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, by telephone at (800)
747-3924 or by e-mail at prospectus@pjc.com. Vanda intends to file a final
prospectus supplement relating to the offering with the SEC, which will be
available along with the accompanying prospectus filed with the SEC in
connection with the shelf registration, on the SEC's website at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of
an offer to buy any securities of Vanda, nor shall there be any sale of
securities in any state or jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. This press release is being
issued pursuant to and in accordance with Rule 134 under the Securities Act of
1933, as amended.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the
development and commercialization of products for the treatment of central
nervous system disorders. For more information on Vanda, please visit
www.vandapharma.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events,
trends and business prospects, which may affect Vanda's future operating
results and financial position. Such statements, including, but not limited
to, those regarding statements about Vanda's expectations regarding its
fundraising efforts, including the closing of the public offering, the
anticipated use of proceeds from the offering and the underwriter's exercise
of its over-allotment option, involve known and unknown risks that relate to
Vanda's future events or future financial performance and the actual results
could differ materially from those discussed in this communication. Risks and
uncertainties that may cause Vanda's actual results to differ materially from
those discussed in this communication can be found in the "Risk Factors"
section of Vanda's Form 10-K, Forms 10-Q and its other filings with the
Securities and Exchange Commission. Readers are cautioned not to place undue
reliance on these forward-looking statements that speak only as of the date
hereof, and Vanda assumes no responsibility to update or revise any
forward-looking statements contained in this communication to reflect events,
trends or circumstances after the date of this communication.

Company Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

Media Contact:
Laney Landsman
Assistant Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com



SOURCE Vanda Pharmaceuticals Inc.

Website: http://www.vandapharma.com
 
Press spacebar to pause and continue. Press esc to stop.